Limnopharma, specialized in the development of new therapies for various retinal diseases, has been named one of the 100 best startups of 2023 by the Spanish Association of Science and Technology Parks (APTE).

The company focuses on the development of new treatments for retinal diseases that affect more than 200 million people worldwide, such as Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP).

“We are very proud to have been named one of the 100 best startups of 2023,” said Elena Puerta-Fern├índez, CEO of Limnopharma. “This recognition is a great boost for us, as it will help us continue to advance in our goal of developing new therapies for these ocular diseases that pose a major social and economic problem.”

Limnopharma is currently developing its first product, LIM21, a treatment for RP. LIM21 has shown its efficacy in trials in animal models of the disease, and the company expects to initiate clinical trials in humans in 2024.

In addition to LIM21, Limnopharma is developing other products to treat dry AMD, diabetic retinopathy, or cataracts.

The selection of Limnopharma as one of the 100 best startups of 2023 is a recognition of its potential to develop new therapies that can improve the quality of life for millions of people around the world.